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We read with interest the recent article by Jabro et al.
[1] on splenic irradiation in patients with chronic myeloid
leukemia (CML) undergoing allogeneic bone marro w
transplantation (BMT). In their single-center study based
on 37 patients who received splenic treatment with
5 0 0 cGy in 5 daily fractions, they conclude that additional
splenic irradiation before BMT may be well tolerated, may
have a lower relapse rate, and may have a favorable influ-
ence on results. They postulate that the findings deserv e
f u rther investigation. Their re p o rt stimulated us to re -
review the prospective, randomized, splenic irr a d i a t i o n
study by the European Group for Blood and Marro w
Transplantation (EBMT) that was initiated in May 1986
and closed in May 1990.
The study by EBMT has been published extensively
[2-4]. In brief, the study included 229 patients: 147 men and
81 women with a median age of 33 years (range, 8-52 years);
115 patients were randomly chosen to receive splenic irradi-
ation and 114 did not receive splenic irradiation. For ran-
domization, patients were stratified by age (<25 years,
>25 years) and according to whether or not T-cell depletion
was used. The patients were treated in 30 European centers
(Appendix 1). The study population consisted of patients
with CML in the first chronic phase who were awaiting
BMT from a sibling donor with identical HLA antigen.
Splenic irradiation was off e red to the participating centers
in 3 options: 10 Gy as a single dose (52 patients), 2 doses of
5 Gy (28 patients), and 3 doses of 3.3 Gy (35 patients).
Splenic irradiation had to be given within 14 days preceding
transplant. The transplant conditioning regimen (92% of
the patients with a regimen including total body irr a d i a-
tion), graft-versus-host reaction prophylaxis, and supportive
c a re during the transplant period were provided accord i n g
to the local protocol of each center. 
The study was last updated in 1995 and published in
1996 [4]. Both groups of patients were similar with regard to
pretransplant factors. In brief, for both groups, survival, dis-
e a s e - f ree survival, transplant-related mort a l i t y, and re l a p s e
incidence were similar when all 229 patients were analyzed
together. A difference was found in a subgroup analysis [4].
Patients with no T-cell depletion and with more than 3%
basophils in the peripheral blood prior to transplant had
significantly fewer relapses when they received splenic irra-
diation. The results were confirmed in a multivariate analysis.
This reduced-relapse rate in a subgroup of patients had not
yet translated into a significantly improved survival for the
whole group because of a slightly increased risk of transplant-
related mortality in the same cohort. 
The update as of September 1, 1999, re c o n f i rms the
previous analysis. There is a slight trend for better survival
for patients in the splenic irradiation group (Figure 1). The
d i ff e rence is significant (P <.05) within the subgroup of
patients with no T-cell depletion and more than 3% basophils
prior to transplant. 
This update is in line with the report by Jabro et al. [1]
and others [5,6] that, under certain conditions, additional
reduction of tumor load prior to BMT may be beneficial.
This appears not to be the case in patients at very high risk
for relapse (eg, T-cell depletion or blast crisis), patients with
very low risk of relapse, or patients with non–T-cell depleted
transplantations with signs of early pro g ressive disease such as
high basophil counts. Splenic treatment should indeed be
re c o n s i d e red in BMT treatment schedules for patients with
CML and signs of early pro g ressive disease. 
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APPENDIX 1
List of participating centers included in the EBMT:
Basel: Kantonsspital (B. Speck, A. Gratwohl);
Berlin: Universitätsklinikum Rudolf Vi rchows (W. Siegert ) ;
B i rmingham: Queen Elizabeth Hospital (I.M. Franklin);
B russels: Institut J. Bordet (L. Debusscher), Hôpital Univer-
s i t a i re St. Luc (A. Ferr a n t ) ;
Caen: Centre Hospitalier (X. Tro u s s a rd ) ;
Copenhagen: University Hospital (N. Jacobsen);
C o rdoba: Hospital Reine Sofia (A. To rre s - G o m e z ) ;
Créteil: Hôpital H. Mondor (J.-P. Ve rn a n t ) ;
Dublin: St. James’ Hospital (S.R. McCann);
E d i n b u rgh: Royal Infirm a ry (A.C. Parker);
Genova: Ospedale San Martino (A. Bacigalupo, F. Frassoni);
Hanover: Med. Hochschule (H. Link);
Helsinki: University of Helsinki (T. Ruutu, L. Vi o l i n ) ;
Huddinge: Karolinska Institute (B. Lössqvist, G. Gahrton, 
O. Ringdén);
Innsbruck: Universitätsklinik für Innere Medizin 
(D. Niederwieser);
Kiel: Christian Albrechts-Universität (N. Schmitz);
Leiden: University Hospital (F.E. Zwaan, W. Fibbe);
Lisbon: Inst. Portugues Oncologia (M. Abecasis);
London: Harley Street Clinic (P. Gravett), Royal Marsden
Hospital (R. Powles, G. Helenglass), Royal Free Hospital
(H.G. Pre n t i c e ) ;
Munich: Ludwig Maximilians-Universität (H.-J. Kolb);
Nijmegen: Sint Radboudziekenhuis (T. de Witte, 
T. Schattenberg ) ;
Paris: Centre Hospitalier St. Antoine (N.C. Gorin);
Pessac: Centre Hospitalier (J. Reiffers); Riyadh: King Faisal
Hospital (P. Ern s t ) ;
Rome: Università degli Studi di Roma ‘La Sapienza’ (W. Arc e s e ) ;
Santander: Hospital Nacional ‘Marques de Valdecilla’ (A. Iriondo);
Vienna: Allgemeines Krankenhaus der Stadt Wien 
( W. Hinterberger). 
Figure 1. Survival of 229 patients with (yes, 115 patients) or without (no, 114 patients) splenic irradiation prior to bone marrow transplantation for chronic myeloid
l e u k e m i a .
